BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36680177)

  • 1. Patients Treated for HCV Infection and Listed for Liver Transplantation in a French Multicenter Study: What Happens at Five Years?
    Meunier L; Belkacemi M; Pageaux GP; Radenne S; Vallet-Pichard A; Houssel-Debry P; Duvoux C; Botta-Fridlund D; de Ledinghen V; Conti F; Anty R; Di Martino V; Debette-Gratien M; Leroy V; Gerster T; Lebray P; Alric L; Abergel A; Dumortier J; Besch C; Montialoux H; Samuel D; Duclos-Vallée JC; Coilly A
    Viruses; 2022 Dec; 15(1):. PubMed ID: 36680177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation.
    Pascasio JM; Vinaixa C; Ferrer MT; Colmenero J; Rubin A; Castells L; Manzano ML; Lorente S; Testillano M; Xiol X; Molina E; González-Diéguez L; Otón E; Pascual S; Santos B; Herrero JI; Salcedo M; Montero JL; Sánchez-Antolín G; Narváez I; Nogueras F; Giráldez Á; Prieto M; Forns X; Londoño MC
    J Hepatol; 2017 Dec; 67(6):1168-1176. PubMed ID: 28842296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting.
    Perricone G; Duvoux C; Berenguer M; Cortesi PA; Vinaixa C; Facchetti R; Mazzarelli C; Rockenschaub SR; Martini S; Morelli C; Monico S; Volpes R; Pageaux GP; Fagiuoli S; Belli LS;
    Liver Int; 2018 Dec; 38(12):2170-2177. PubMed ID: 29750389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study.
    Ferrarese A; Germani G; Gambato M; Russo FP; Senzolo M; Zanetto A; Shalaby S; Cillo U; Zanus G; Angeli P; Burra P
    World J Gastroenterol; 2018 Oct; 24(38):4403-4411. PubMed ID: 30344424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals.
    Zanetto A; Shalaby S; Vitale A; Mescoli C; Ferrarese A; Gambato M; Franceschet E; Germani G; Senzolo M; Romano A; Angeli P; Rugge M; Farinati F; Forton DM; Cillo U; Burra P; Russo FP
    Liver Transpl; 2017 Sep; 23(9):1103-1112. PubMed ID: 28544587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
    Krassenburg LAP; Maan R; Ramji A; Manns MP; Cornberg M; Wedemeyer H; de Knegt RJ; Hansen BE; Janssen HLA; de Man RA; Feld JJ; van der Meer AJ
    J Hepatol; 2021 May; 74(5):1053-1063. PubMed ID: 33242501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Considerations When Treating Hepatitis C in a Cirrhotic Transplant Candidate.
    Daniel KE; Said A
    Curr Gastroenterol Rep; 2018 Apr; 20(5):20. PubMed ID: 29623506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HCV Eradication with Direct-Acting Antivirals Does Not Impact HCC Progression on the Waiting List or HCC Recurrence after Liver Transplantation.
    Emamaullee JA; Bral M; Meeberg G; Montano-Loza AJ; Bain VG; Burak KW; Bigam D; Shapiro AMJ; Kneteman N
    Can J Gastroenterol Hepatol; 2019; 2019():2509059. PubMed ID: 30775356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
    Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
    J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delisting and clinical outcomes of liver transplant candidates after hepatitis C virus eradication: A long-term single-center experience.
    Nabatchikova EA; Abdurakhmanov DT; Rozina TP; Nikulkina EN; Tanaschuk EL; Moiseev SV
    Clin Res Hepatol Gastroenterol; 2021 Nov; 45(6):101714. PubMed ID: 33930587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver transplant listing for hepatitis C-associated cirrhosis and hepatocellular carcinoma has fallen in the United Kingdom since the introduction of direct-acting antiviral therapy.
    Vaziri A; Gimson A; Agarwal K; Aldersley M; Bathgate A; MacDonald D; McPherson S; Mutimer D; Gelson W
    J Viral Hepat; 2019 Feb; 26(2):231-235. PubMed ID: 30339294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of hepatitis C-related liver transplantation in direct-acting antiviral era.
    Choudhary NS; Saraf N; Saigal S; Rastogi A; Bhangui P; Thiagrajan S; Soin AS
    Indian J Gastroenterol; 2020 Dec; 39(6):539-543. PubMed ID: 33230754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A notable proportion of liver transplant candidates with alcohol-related cirrhosis can be delisted because of clinical improvement.
    Pose E; Torrents A; Reverter E; Perez-Campuzano V; Campos-Varela I; Avitabile E; Gratacós-Ginès J; Castellote J; Castells L; Colmenero J; Tort J; Ginès P; Crespo G
    J Hepatol; 2021 Aug; 75(2):275-283. PubMed ID: 33746085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of Direct-acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients With Hepatocellular Carcinoma Listed for Liver Transplantation: An International Multicenter Study.
    Gorgen A; Galvin Z; Huang AC; Vinaixa C; O'Rourke JM; Francoz C; Hansen BE; Durand F; Elsharkawy AM; Shah T; Berenguer M; Rubin A; Calatayud D; Mehta N; Terrault NA; Lilly LB; Selzner N; Sapisochin G
    Transplantation; 2020 Oct; 104(10):2087-2096. PubMed ID: 31978002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term survival and clinical outcomes following direct-acting antiviral (DAA) treatment in HCV decompensated cirrhosis in Brazil: a real-world study.
    Pereira GH; Peixoto HR; Giusti ML; Souza ML; Victor LB; Fernandes F; Perez RM; Villela-Nogueira CA
    Braz J Infect Dis; 2022; 26(5):102697. PubMed ID: 36037847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study.
    Belli LS; Berenguer M; Cortesi PA; Strazzabosco M; Rockenschaub SR; Martini S; Morelli C; Donato F; Volpes R; Pageaux GP; Coilly A; Fagiuoli S; Amaddeo G; Perricone G; Vinaixa C; Berlakovich G; Facchetti R; Polak W; Muiesan P; Duvoux C;
    J Hepatol; 2016 Sep; 65(3):524-31. PubMed ID: 27212241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct-Acting Antivirals and Hepatocellular Carcinoma: No Evidence of Higher Wait-List Progression or Posttransplant Recurrence.
    Piñero F; Boin I; Chagas A; Quiñonez E; Marciano S; Vilatobá M; Santos L; Anders M; Hoyos Duque S; Soares Lima A; Menendez J; Padilla M; Poniachik J; Zapata R; Maraschio M; Chong Menéndez R; Muñoz L; Arufe D; Figueroa R; Mendizabal M; Hurtado Gomez S; Stucchi R; Maccali C; Vergara Sandoval R; Bermudez C; McCormack L; Varón A; Gadano A; Mattera J; Rubinstein F; Carrilho F; Silva M
    Liver Transpl; 2020 May; 26(5):640-650. PubMed ID: 32133773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Italian compassionate use of sofosbuvir in HCV patients waitlisted for liver transplantation: A national real-life experience.
    Martini S; Donato MF; Mazzarelli C; Rendina M; Visco-Comandini U; Filì D; Gianstefani A; Fagiuoli S; Melazzini M; Montilla S; Pani L; Petraglia S; Russo P; Trotta MP; Carrai P; Caraceni P;
    Liver Int; 2018 Apr; 38(4):733-741. PubMed ID: 28921807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of hepatitis C virus (HCV) antiviral treatment on the need for liver transplantation (LT).
    Sáez-González E; Vinaixa C; San Juan F; Hontangas V; Benlloch S; Aguilera V; Rubín A; García M; Prieto M; López-Andujar R; Berenguer M
    Liver Int; 2018 Jun; 38(6):1022-1027. PubMed ID: 29105320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry.
    Belli LS; Perricone G; Adam R; Cortesi PA; Strazzabosco M; Facchetti R; Karam V; Salizzoni M; Andujar RL; Fondevila C; De Simone P; Morelli C; Fabregat-Prous J; Samuel D; Agarwaal K; Moreno Gonzales E; Charco R; Zieniewicz K; De Carlis L; Duvoux C;
    J Hepatol; 2018 Oct; 69(4):810-817. PubMed ID: 29940268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.